Although TKIs have significantly enhanced the survival of patients with NSCLC with EGFR mutations, potential cardiotoxicity, especially fatal arrhythmia, threatens the benefit of long-term mortality and morbidity (9, 10). Here, EGFR is linked to non-small cell lung carcinoma.